Get started
Silbert

Cassava | Big support - last chance to get in cheap?

Long
Cassava Sciences, Inc. (NASDAQ:SAVA)  
Silbert Updated   
NASDAQ:SAVA   Cassava Sciences, Inc.
Trend Analysis
4
13
trendanalysis
“Cassava Sciences had a productive quarter with its research programs in Alzheimer’s disease,” said Remi Barbier, President & CEO . “As a result, we anticipate having top-line results for our Phase 2b study of PTI-125, our lead drug candidate for Alzheimer’s, earlier than mid-2020.”

Just keep in mind - the phase IIb data will be reported within days or a few weeks!
Comment:
Stock of the year!
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.